Fear and Loathing in the Cannabis Industry (Part 2): Treaty Authority, Schedule III, and the Continued Illusion of Progress
"There is no honest way to explain this without admitting that the truth is ugly."
I used that Hunter S. Thompson line four months ago when I wrote that Trump's cannabis executive order was political theater, carefully staged, dressed in a lab coat, and received in the cannabis industry with a standing ovation nobody had earned. The thesis then was simple. Schedule III wasn't reform. It was recalibration. It wasn't a green light. It was a spotlight.
On April 22, 2026, Acting Attorney General Todd Blanche signed the rule.
On April 23rd, the Office of Legal Counsel certified the copy for the Federal Register.
The headlines came fast.
The cheering came faster.
The industry that spent the last sixty days rehearsing a victory speech is already drafting press releases about a "new era."
Now, before anyone goes popping champagne bottles, just a reminder that the champagne contains more measurable regulatory relief than this order does… for most cannabis operators.
Because here is what the headlines leave out: the April 22 rule rescheduled part of cannabis. Not cannabis. Part of cannabis. The rest of it is scheduled for a completely separate hearing starting June 29, and that hearing is a restart of the whole 2024 rulemaking the prior administration left unfinished.
Two tracks. Two processes. Two very different levels of finality. The industry reaction has been treating them as one event. THEY ARE NOT ONE EVENT.
Let’s walk through what actually happened, because precision here matters more than current enthusiasm.
What AG Order 6754-2026 Actually Does
Strip away the political spin (and the oversized positive reaction) and the rule is narrower than the headlines suggest by a considerable margin.
The April 22 order reschedules only two categories of marijuana to Schedule III:
FDA-approved drug products containing marijuana (like Marinol)
Marijuana subject to a qualifying state medical marijuana license (including naturally derived Δ9-THC contained in either of the above)
That's the universe of rescheduled cannabis as of today. That's the whole list.
Notice what isn't on it.
What stayed in Schedule I:
Recreational (adult-use) marijuana in every state that permits it. Colorado. California. Massachusetts. Illinois. Michigan. New York. Every state where cannabis is sold to adults without a medical qualification remains, under federal law, classified alongside heroin and LSD.
Unlicensed bulk marijuana, marijuana extract, and Δ9-THC material used as inputs to make FDA-approved drug products. The finished FDA product is Schedule III. The raw material going into it stays Schedule I until it's inside the approved product. DEA drafted the rule that way deliberately, to preserve import, quota, and registration obligations under the Single Convention.
Synthetic THC, delta-10-THC, and every synthetic cannabinoid produced through artificial processes.
Any marijuana that isn't covered by an FDA approval or a state medical license.
The rule walks past those categories entirely. It steps over them like a politician avoiding eye contact to dodge an interviewer’s question.
The procedural story is just as specific. The order was issued under 21 U.S.C. 811(d)(1), which is the treaty-based expedited scheduling authority. That statute exists because the United States has obligations under the 1961 Single Convention on Narcotic Drugs to control substances a certain way, and Congress gave the Attorney General a fast path to issue orders that satisfy those obligations.
The fast path has a price tag attached. Orders issued under 811(d)(1) are explicitly exempt from the notice-and-comment procedures of the Administrative Procedure Act. No public comment period. No rulemaking hearing. No HHS scientific evaluation requirement (the HHS recommendation from 2023 is referenced, but using it is discretionary under 811(d)(1)). Not a "major rule" under the Congressional Review Act. Not a "significant regulatory action" under Executive Order 12866.
Thirty-four pages. Signed Wednesday. Certified Thursday. Effective the moment the Federal Register clerks process the transmission. Treaty authority, 811(d)(1), and a pen.
The Two-Track Play Nobody Is Reading Carefully
This is the part the victory-lap coverage is missing.
The April 22 order does not close the rescheduling question. It closes one track of it. A second, broader rulemaking is already scheduled, and it is scheduled through the full 811(a)/(b) procedural process that the treaty route bypassed.
Track A: the treaty-authority route. What happened on April 22. A narrow, final, immediately effective rescheduling of FDA-approved marijuana products and state-licensed medical marijuana, issued under 811(d)(1). No hearing. No comment. Unilateral. Done.
Track B: the broader rulemaking. The DEA administrative hearing scheduled to run from June 29 through July 15, 2026, at the DEA Hearing Facility in Arlington, Virginia, to consider rescheduling the rest of cannabis under 811(a)/(b). The original 811(a)/(b) rulemaking began with the May 21, 2024 NPRM. The December 2, 2024 hearing collapsed. Of the original twenty-five participants, only five remained by November 2024. The administration withdrew the scheduled hearing and is now restarting the process. The December 2024 record is effectively being thrown out. A new docket, a new participant solicitation, a new hearing window.
Six weeks. Including a recess from July 3 through July 6 for the Independence Day 250th. Written notices of intent to participate are due by mail on or before May 20 or electronically on or before May 24. The hearing output produces a record, the record produces a final rule, and that final rule is subject to the full APA, including judicial review.
The two tracks are doing different work for different constituencies.
Track A delivers what the state-licensed medical operators and the pharmaceutical companies with FDA-approved marijuana products needed. Federal 280E relief (described below). A new federal registration pathway at 21 CFR 1301.13(k). Import and export permit access under 21 CFR 1312.30. Federal recognition of state regulatory records "to the maximum extent permissible." Effective on publication. No public process.
Track B is where everything else gets fought about. Adult-use. Recreational. Unlicensed. Legacy. Anyone not already inside the Track A universe.
The asymmetry is not subtle. Track A was done in a day. Track B gets six weeks in a hotel-grade conference facility in Arlington, held in a window that includes a federal holiday recess. The operators who lobbied hardest and had the strongest compliance infrastructure got their piece delivered by treaty authority that cannot be challenged through APA process. Everyone else gets a hearing with an uncertain outcome and a long road after. The lobbyists who paid for the rescheduling got the rescheduling they paid for. The rest of the industry gets a hearing.
What the 280E Story Actually Says
Here is where the difference between the press release and the rule becomes measurable.
Section 280E of the Internal Revenue Code disallows ordinary business deductions for any trade or business "consisting of trafficking in controlled substances... in a schedule I or II." For a decade, it has been the quiet tax weight on every state-legal cannabis operator in America. Move out of Schedule I, and 280E's application shifts.
What the rule actually says: State medical marijuana licensees "will no longer be subject to the deduction disallowance imposed by Section 280E."
Read that sentence again carefully. State medical licensees. Not cannabis businesses generally. Not recreational operators. Not legacy operators. Not unlicensed operators. State medical licensees only, because they are the only ones Track A pulled out of Schedule I.
Adult-use operators remain under 280E. Their substance is still Schedule I. Their deductions are still disallowed. If the same operator runs both a medical line and an adult-use line, the 280E disallowance continues to apply to the adult-use revenue and now produces an even messier tax picture, because the medical side has been separated from the adult-use side by federal schedule.
Retroactive relief is described precisely. The Acting Attorney General "encourages the Secretary of the Treasury to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license." Encourages. Consider. Not a mandate. Not a directive. An encouragement to the Treasury Secretary to consider the question. That is a request to another agency head, delivered in the preamble of a scheduling order, which has no legal force against the IRS or Treasury.
The incumbent operators who were inside the Track A universe got the forward-looking 280E relief immediately (read: CY 2026, the year the rule was made official). Whether they get the backward-looking relief depends on a decision Treasury has not yet made.
The 280E story has winners and losers, and the rule distributes them precisely. Vertically integrated, multi-state medical operators with strong state licensure and clean compliance records are the largest beneficiaries. Adult-use operators are not. Legacy operators who transitioned later or whose documentation trail is thin are not. Operators under social equity programs, many of whom have the narrowest compliance documentation simply because of capital and infrastructure constraints, are structurally at the back of the registration line.
The relief is real. It is also allocated, line by line, to the operators who could most easily have afforded it without the relief, and it bypasses the operators who needed it most.
DEA Is Now the Federal Registration Pathway. Literally.
The rule creates a new federal registration pathway at 21 CFR 1301.13(k) for state medical marijuana licensees. The rule describes it as "cooperative federalism." A more accurate description is that the DEA that enforced prohibition yesterday is the DEA that will issue your federal registration tomorrow.
What the pathway requires:
A valid state medical marijuana license, which the rule treats as "conclusive evidence" of state authorization
A DEA registration application filed within 60 days of Federal Register publication (applicants within that window may continue to operate under their state license while DEA processes the application; DEA must process such applications within six months)
Annual registration fees: $3,699 for manufacturers, $1,850 for distributors, $888 for a three-year dispenser registration
Inventory every two years. Records, reports, and order forms limited to what is "necessary to comply with federal statutory and treaty obligations," with DEA accepting state-required records "to the maximum extent permissible"
State physical-security, labeling, packaging, and disposal requirements accepted in lieu of federal equivalents, subject to the 21 U.S.C. 825(c) warning label
What the pathway does structurally:
DEA registration automatically suspends if the underlying state license is suspended, revoked, or expired. Federal authorization tracks state authorization. A state enforcement action now has federal consequences by operation of the regulation.
For most state medical operators, that is a manageable obligation in the abstract. The complication arrives when you consider what happens to the operators whose state license documentation, renewal history, or compliance record is not as clean as the front-of-house appearance suggests. Every cloudy state licensure issue now has a federal mirror.
And for any registered manufacturer (not state medical licensees, but DEA-registered marijuana manufacturers engaged in the broader federal system), there is a separate mechanism worth noting.
Under the Single Convention's Article 23 obligations, DEA is required to function as the government purchaser of cannabis cultivation. The rule implements this through a nominal-price purchase-and-resale mechanism.
DEA buys the crops from registered manufacturers at a nominal price and sells them back at the same nominal price plus an administrative fee calculated under 21 CFR 1318.06(a). Manufacturers must store crops at facilities to which DEA maintains inspection access on demand. State medical licensees are exempt from this particular provision, but the structural point stands.
So we are clear: DEA is now running a registration pipeline, an import/export permit regime, a physical-inspection authority over manufacturer facilities, a nominal-price purchase-and-resale transaction system, and an administrative fee schedule.
That is not federalism. That is a middleman with a price list.
What the Industry Wants to Believe
The interpretation rolling through cannabis industry social feeds right now is that Schedule III is a "win," a "turning point," a "long-overdue course correction." Some of the language being used is less measured than that. Some of it reads like a bachelor party toast.
Four months ago, I wrote that the industry's willingness to accept crumbs was more worrying than the Executive Order itself. Today I'll extend the observation. The industry's eagerness to interpret crumbs as a meal is the more dangerous habit. Today the crumb has been distributed to a specific subset of operators, accompanied by a six-week hearing in Arlington, VA for everyone else, and the resulting chorus sounds like a full meal has been served.
Schedule III does not legalize cannabis. It did not on December 29, 2025. It did not on April 22, 2026. This order moved a specific subset of cannabis from one federal control schedule to another. That's a regulatory reclassification, not a regulatory retreat. It's an address change, not an amnesty. And it was extended only to the operators who had already built the state-licensure and compliance infrastructure to receive it (read: that Kim Rivers Forbes article had some impeccable timing, right?!?).
The cannabis industry keeps making the same category error: confusing rescheduling with normalization. A drug tightly controlled under Schedule III is still tightly controlled. Testosterone is Schedule III. Tylenol with codeine is Schedule III. Ketamine is Schedule III. Every prescription in that category carries federal recordkeeping, storage, distribution, and reporting obligations that most state cannabis operators have never operated under and wouldn't recognize if they walked into a room full of it.
The compliance burden of Schedule III isn't lighter than Schedule I. It's different, and in some ways heavier, because now there's a federal framework to fit inside instead of a federal prohibition to work around. Prohibition, for all its ugliness, at least told you what the rule was. The new rule is a directory of federal obligations, and it doesn't care what the state program down the hall told you was sufficient. It doesn't care what your trade association emailed you this morning. It is the rule.
Where the Real Risk Is Moving (And This Time It's Not Theoretical)
In December, I wrote that Schedule III would move federal scrutiny from background noise to foreground attention. That was an argument about what would eventually happen if the rulemaking concluded.
A piece of it concluded. Which means the federal agency interest I described in the abstract is now operational. The hypothetical is now an email.
For cannabis testing laboratories specifically, three shifts are already in motion.
Federal agencies are paying attention to data they previously ignored. Once a substance has recognized medical utility under federal law, the quality of the testing data generated around it becomes an agency question, not just a state one. FDA. DEA. HHS. TTB even. Each has a different reason to start asking about cannabis lab data, and none of them ask softly.
The authority gap on federal workplace testing is now live, not hypothetical. The Department of Transportation's drug testing authority runs through HHS Mandatory Guidelines that authorize testing for Schedule I and Schedule II substances. Schedule III is not in that list. Until Congress or HHS addresses that mismatch explicitly, DOT's legal authority to test for marijuana is on shaky ground for any FDA-approved product or state-licensed medical sample. DOT published a compliance notice in December 2025 saying processes remain unchanged until rescheduling was finalized. That notice has now expired for the rescheduled categories.
The bifurcation between medical and adult-use cannabis creates a compliance landscape that was already difficult to navigate. A cannabis testing lab in a state with both medical and adult-use programs is now, under federal law, testing two different scheduled substances with two different federal classifications. The sample analyzed for a medical dispensary or cultivator is a Schedule III substance. The sample analyzed for an adult-use operator down the street is a Schedule I substance. The analytical method may be identical. The regulatory frame around it is not. The paperwork will not resolve itself quietly.
That asymmetry is going to generate lawsuits, inspection questions, and regulatory correspondence that nobody's SOPs currently answer.
What This Means for Cannabis Testing Labs Specifically
The short version. The operational day-to-day hasn't changed. The regulatory horizon has.
State testing requirements are untouched. Potency panels, contaminant panels, heavy metal panels, pesticide panels, residual solvent panels, and microbial panels continue under existing state frameworks. Method validation requirements set by state programs continue. Proficiency testing requirements continue. Accreditation obligations under ISO 17025 continue.
What changes is the audience that might eventually ask to see all of that work.
Before today, the worst-case audit for a cannabis testing lab was a state program auditor plus an occasional accreditation reassessment. After, the list of entities with a plausible reason to review cannabis testing data expands to include federal agencies whose expectations around data integrity, method defensibility, and documentation coherence are calibrated to pharmaceutical and clinical laboratory standards, not state cannabis standards. Those are very different standards, written by very different people, for very different reasons.
The gap between "passing a state audit" and "surviving an FDA data integrity review" is not a matter of degree. It's a matter of kind.
I've sat in laboratories across both worlds. State cannabis inspections tend to focus on whether required documents exist, whether licensed personnel performed licensed activities, and whether results were reported within the required window. Federal data integrity reviews ask different questions. They ask whether the data you reported can be reconstructed from raw files. They ask whether abandoned runs were documented and explained. They ask whether the validation package for a method reflects the method as currently practiced, or the method as originally validated three years ago, on an instrument that's been replaced twice since. They ask whether electronic records meet 21 CFR Part 11 requirements for attribution, legibility, contemporaneity, originality, and accuracy. That's the ALCOA+ framework. It's not a suggestion.
Most cannabis testing laboratories today were never designed to answer that second set of questions. That isn't a judgment. It's a description of how the industry was built. State cannabis programs defined the compliance requirements, state auditors enforced them, and labs optimized for passing state audits. That optimization is exactly what you'd expect. It's also the optimization that creates exposure when a different standard shows up at the door.
What Cannabis Testing Labs Should Do This Week
Don't rewrite your SOPs. Don't panic-call your accreditation body. Don't respond to this news with an emergency training session that creates fresh documentation gaps on top of the ones you already had.
Do take three specific actions in the next thirty days.
First, pull your method validation packages and read them as if a federal reviewer is asking for them. For each validated method, ask whether the documented validation still describes the method as you actually run it today. If the instrument has been replaced, if the reference standards have changed vendors, if the matrices have expanded, if the acceptance ranges have been adjusted (any of which is normal), is there a documentation trail that explains those changes, or is the validation on file effectively a historical artifact? That gap is the single largest defensibility risk most cannabis labs have. It is invisible until somebody asks.
Second, audit your data handling for reconstruction. Pick a recent reported result. Trace it back through the instrument software, the raw data files, the QC records, the analyst's training file, and the release decision. Can you reconstruct it cleanly, from raw to reported? If the path has gaps, if abandoned runs are missing, if review signatures are unclear, if audit trail entries are orphaned, that is what a federal data integrity reviewer would find. Fix it before anyone looks.
Third, document the decisions you haven't documented. The way most cannabis labs operate, significant operational choices live in the quality manager's head. Which proficiency tests you subscribe to, and why. Why you set QC limits where you set them. How you decide to release a borderline result. Why you chose the SOP revision interval you chose. Federal reviewers don't assume. They ask, and they write the answer down. If the answer lives only in somebody's memory, it doesn't exist for compliance purposes, and it certainly doesn't exist for the record.
Those three items are work. They aren't dramatic. They don't make a press release. They are what actually moves a state-optimized laboratory toward federal defensibility, and doing them now, while there's no specific pressure, is significantly easier than doing them under a specific inspection timeline. The right time to patch the roof is not when the rain starts.
The June 29 Hearing: Six Weeks for a Fifty-Six-Year System
The partial rescheduling is not the end of this story. It's the intermission.
The 811(a)/(b) administrative hearing launching June 29 at the DEA Hearing Facility in Arlington will consider the rescheduling of all marijuana not already moved by Track A. Adult-use. Recreational. Unlicensed. Legacy. The hearing is scheduled to conclude no later than July 15. The record that hearing produces will shape whatever final rule emerges, which will itself be subject to the full Administrative Procedure Act, to judicial review, and to whatever congressional interference attaches along the way.
Six weeks, including a holiday recess from July 3 through July 6 for the Independence Day 250th (excuse my lack of enthusiasm for all the semiquincentennial brouhaha).
Cannabis has been in Schedule I since 1970. Fifty-six years. The procedural window the administration has allocated to hear the record for rescheduling everything not already moved is approximately six weeks. That ratio is not inadequate. It is revealing. It is what you schedule when you have decided the outcome you want and you need the process to produce it. Two weeks of testimony, one week of rebuttal, a holiday recess, and then a final rule drafted against whatever the record allegedly supports (don’t forget about the lobbyists).
Twenty-two US senators, including Mitch McConnell, sent the President a letter warning that rescheduling cannabis poses health and economic threats to the nation. Which is what you say when you want the policy to fail without admitting you want it to fail. The same incumbent interests that gutted hemp after the 2018 Farm Bill are not going to sit quietly through a broader rescheduling debate. They never do. They don't have to. They have the lawyers.
For cannabis testing laboratories, the planning frame for the next eighteen months should assume further regulatory change, not consolidation. That means validation packages that can absorb a change in regulatory frame. Quality systems that can extend to cover new scope without being rebuilt. Documentation practices that don't depend on a specific federal classification holding still. Labs that get this right will be positioned to serve medical and adult-use markets, investigational research, and whatever federal-contract opportunities open up if rescheduling expands through Track B.
Labs that don't are going to keep running the current compliance program and discover, probably during an inspection, that the compliance program was never the defensibility program. Those are different things. One of them passes the audit. The other one survives what comes after.
Consolidation Is the Second-Order Effect
Track A does not just reschedule a narrow slice of cannabis. It reorders the economics of who testing laboratories will be testing for in eighteen months.
The 280E relief, the federal registration pathway, and the state-license-conclusive-evidence provision all run through the same filter. They favor operators with documented state compliance history, with capital to navigate the DEA registration process, with legal counsel to navigate the 21 CFR Part 1301 requirements, and with the cash-flow slack to absorb fees and inspection infrastructure. That describes the larger multi-state medical operators and the pharmaceutical companies with FDA-approved marijuana products. It does not describe most smaller, equity-licensed, or legacy operators.
Consolidation was already underway in cannabis. This rule accelerates it. State-license volume is about to shift. Testing volume follows state-license volume. A lab strategy that assumes the 2025 cultivator count in 2027 is a lab strategy that is going to be underwater. The question for any cannabis testing laboratory reading this in April 2026 is not whether consolidation is coming. It is whether the laboratory's customer base will still look the same in eighteen months, and what the laboratory's service model needs to become if the customer base reshapes around federally-registered medical operators and FDA-approved product manufacturers.
That is an operational question with a commercial tail. Labs that answer it early get to choose their positioning. Labs that answer it late get positioned by the market.
The Illusion of Progress Has a Shelf Life
Four months ago, I wrote that Trump might get the credit but the industry still got the consequences. That framing still holds. This order doesn't change who pays for the gap between political narrative and operational reality. It just accelerates the timeline for half the industry and schedules a hearing in Arlington for the other half.
The cannabis testing laboratories that quietly start aligning their systems, before anyone forces the issue, are the ones who survive what comes next. The ones who accept the victory lap as the victory are going to get caught flat-footed when expectations tighten, as they always do when a substance moves into a federally recognized medical framework, and as they almost certainly will again if Track B produces a broader final rule later this year.
Federal scrutiny doesn't arrive with sirens. It arrives with questions. Specific ones. Written down. With a return address.
Schedule III is now half official. The questions are coming for the half already inside the framework. The questions are coming for the half still outside it. The labs (and other cannabis businesses) that prepared for them during the months of rulemaking will answer them calmly. Anyone that treated the rulemaking as political theater will discover that political theater has real consequences once the curtain comes down. The people who wrote the press releases will not be the ones answering the questions.
The illusion of progress was always going to have a shelf life. Today the timer started.
FAQ
What did AG Order 6754-2026 actually do on April 22, 2026?
Acting Attorney General Todd Blanche signed a Department of Justice final rule, issued under 21 U.S.C. 811(d)(1) treaty authority, reclassifying two specific categories of marijuana from Schedule I to Schedule III of the Controlled Substances Act: FDA-approved drug products containing marijuana, and marijuana regulated under a qualifying state medical marijuana license. Recreational (adult-use) cannabis, unlicensed marijuana, synthetic THC, and bulk marijuana inputs to FDA-approved products all remain in Schedule I. The rule is effective upon Federal Register publication and is exempt from APA notice-and-comment procedures because it was issued under treaty authority.
Does the April 22 rescheduling order apply to adult-use (recreational) cannabis?
No. The rule rescheduled only FDA-approved marijuana drug products and marijuana subject to a state medical marijuana license. Adult-use cannabis in every state remains Schedule I under federal law. A separate administrative hearing under 21 U.S.C. 811(a)/(b) is scheduled at the DEA Hearing Facility in Arlington, Virginia from June 29 through July 15, 2026, to consider rescheduling the rest of cannabis. That process restarts the 2024 rulemaking that was withdrawn in late 2024.
Who gets 280E tax relief under the new rule?
State medical marijuana licensees. The preamble to AG Order 6754-2026 states that state licensees "will no longer be subject to the deduction disallowance imposed by Section 280E of the Internal Revenue Code." Adult-use operators are not covered. Retroactive relief for prior tax years is described as a request: the Acting Attorney General "encourages the Secretary of the Treasury to consider" providing retrospective 280E relief for years in which a state licensee operated under a state medical license. Retroactive relief is a recommendation to Treasury, not a directive.
Does Schedule III rescheduling change how cannabis testing laboratories operate day-to-day?
Not immediately. State testing requirements (potency, contaminants, heavy metals, pesticides, residual solvents, microbials) remain in effect under existing state frameworks. ISO 17025 accreditation obligations and state-mandated method validation, proficiency testing, and reporting continue unchanged. What changes is the regulatory horizon: federal agencies now have a clearer basis to review cannabis testing data under frameworks calibrated to pharmaceutical and clinical laboratory standards.
What's the difference between a state cannabis lab audit and a federal data integrity review?
A state cannabis audit typically verifies that required documents exist, licensed personnel performed licensed activities, and results were reported within required windows. A federal data integrity review asks whether reported data can be reconstructed from raw files, whether abandoned runs are documented and explained, whether validation packages reflect methods as currently practiced, and whether electronic records meet 21 CFR Part 11 and ALCOA+ expectations. The two reviews ask different questions and apply different standards.
What is the new DEA registration pathway for state medical marijuana licensees?
The rule creates an expedited DEA registration pathway at 21 CFR 1301.13(k). State medical marijuana license holders may apply within 60 days of Federal Register publication and operate under state license during DEA's review (DEA must complete review within six months). State license is treated as "conclusive evidence" of state authorization. DEA registration automatically suspends if the underlying state license is suspended, revoked, or expires. Annual fees: $3,699 for manufacturers, $1,850 for distributors, $888 for a three-year dispenser registration.
What should a cannabis testing lab do differently after the April 2026 rescheduling order?
Three actions in the next thirty days: (1) audit method validation packages to confirm they describe each method as currently practiced, with documented rationale for any changes; (2) trace a recent reported result from raw instrument data through to release and confirm the path reconstructs cleanly with no documentation gaps; (3) document the significant operational decisions that currently live only in the quality manager's head, including SOP revision intervals, QC limit rationale, and release decision criteria.
Does the rescheduling affect DOT or workplace drug testing for marijuana?
The legal authority for DOT drug testing runs through HHS Mandatory Guidelines that authorize testing for Schedule I and Schedule II substances. Schedule III is not currently in that list. Until HHS or Congress addresses the mismatch explicitly for rescheduled categories, DOT's authority to test for FDA-approved or state-medical marijuana under the current framework is uncertain. DOT published a compliance notice in December 2025 stating processes remain unchanged until rescheduling was finalized. With AG Order 6754-2026 signed, that holding pattern has expired for the rescheduled categories. Adult-use (Schedule I) testing authority is unaffected.
When will the rest of cannabis (adult-use) potentially be rescheduled?
An administrative hearing under 21 U.S.C. 811(a)/(b) is scheduled to run from June 29 through July 15, 2026, at the DEA Hearing Facility in Arlington, Virginia, to consider broader rescheduling of all marijuana not covered by AG Order 6754-2026. The hearing restarts the 2024 rulemaking that was withdrawn after the December 2024 hearing collapsed. Written notice of intent to participate is due by May 20 (mail) or May 24 (electronic). The outcome and downstream rulemaking timeline are uncertain. Past federal rulemaking on cannabis has taken years and been significantly shaped by congressional pushback.
Ron Brooks is the founder of Ron Brooks Consulting, providing cannabis testing laboratory consulting, federal regulatory readiness advisory, and analytical laboratory consulting for operators preparing for federal scrutiny under the post-Schedule III regulatory frame. To discuss how your laboratory's compliance program holds up under federal review, schedule a consultation.
